


Slide 1 Slide 2






Slide 3 Slide 4






Slide 5 Slide 6





Slide 7 Slide 8



Board Composition Florida Board of Optometry is comprised of 7 members Licensed practitioners Consumer members Citizens of Florida Non – optometrists No connections with any practice of optometry or vision related business or profession One must be over 60 years of age


Slide 9 Slide 10






Slide 11 Slide 12







Slide 13 Slide 14






Slide 15 Slide 16






Slide 17 Slide 18







Slide 19 Slide 20






Slide 21 Slide 22





Slide 23 Slide 24







Slide 25 Slide 26

On March 26, 2025, the Florida Board of Optometry issued a Final Order approving the Petitioner's use of Lumenis Stellar M22, also known as Optilight, to provide intense pulse light (IPL) therapy for the treatment of dry eye disease caused by Meibomian Gland Dysfunction.


Any optometrist shall not use or perform any technique, function or mode of treatment which the optometrist is not professionally competent to perform. Professional competence is acquired by the following: Formal education Supervised training and experience Continuing education approved by the board Combination of the above

Slide 27 Slide 28






Slide 29 Slide 30







Slide 31 Slide 32



A licensed practitioner shall provide that degree of care which conforms to that level of care provided by medical practitioners in the same or similar communities.

https://www.floridaoptometry.gov and https://www.flhealthsource.gov 463.0135





Slide 35 Slide 36

A licensed practitioner shall promptly advise a patient to seek evaluation by a physician skilled in diseases of the eye and licensed under chapter 458 or chapter 459 for diagnosis and possible treatment whenever the licensed practitioner is informed by the patient of the sudden onset of spots or "floaters" with loss of all or part of the visual field.


Visual Fields?????


https://www.floridaoptometry.gov and https://www.flhealthsource.gov

A licensed practitioner who believes a patient may have glaucoma shall promptly advise the patient of the serious nature of glaucoma. The licensed practitioner shall place in the patient's permanent record that the practitioner provided such advice to the patient.

https://www.floridaoptometry.gov and https://www.flhealthsource.gov


Slide 37 Slide 38







Slide 39 Slide 40






Slide 41 Slide 42





Slide 43 Slide 44



E-Licensing 2023 Electronic licenses replaced the of mailing paper-based licenses. Licenses will be able to be retrieved through the MQA Online Services Portal. Licenses will be available 2 days after application approval Licensees must print out and display their new license according to Chapter 463 Free of charge New licenses will have a QR code attached

Slide 45 Slide 46

Background Screening Requirements Passed in the 2024 legislative session Beginning July 1, 2025 all applicants must submit electronic fingerprints before an initial license is issued. All renewals will need to be fingerprinted before the next biennium. No screening= No license Start early...process takes time

New Application Requirement

Introduction

 House Bill 975, Background Screening and Certifications, passed during the 2024 Legislative Session, establishing background screening requirements for health care professions regulated by the Florida Department of Health, Division of Medical Quality Assurance.



 <u>Beginning July 1, 2025</u>, all applicants must submit electronic fingerprints before an initial license is issued.

Florida HEALTH

46

Slide 47

Slide 48

How It Works

Act Now - Don't Delay!


Know Your Timeline.

- The background screening process takes time due to multiple steps and processing delays.
- to multiple steps and processing delays.

 Waiting too long can result in **licensing delays**.

What Happens if You Don't Comply?

- · No background screening = No license.
- You cannot obtain your license without completing this requirement.





- 1. Register with the CHAI system.
 - Go to chai.flclearinghouse.com/
- 2. Create or update your profile.
 - If you're a new user, complete the registration process.
 - If you've registered before, ensure your profile is up to date.





Slide 49 Slide 50

- 3. Schedule an appointment with a Livescan provider.
 - Use the CHAI system or visit the Locate a Provider page at https://filhealthsource.gov/backgroundscreening/bgs-providers/

Important:

You are responsible for screening costs – fees vary by provider. Check pricing and availability in advance to avoid delays!



4. Bring your ORI Number to your Fingerprinting Appointment.

- ORI Numbers can be found at filhealthsource.gov/backgroundscreening/bgs-requirements/.
- Request your Transaction Control Number (TCN).
 - Before you leave, ask the Livescan provider for your TCN to track your results.
 - Important: The Department cannot retrieve your TCN if you lose it.



Florida HEALTH Florida HEALTH

Slide 51

Slide 52

Track the submission of your prints by entering your TCN at the Florida

Department of Law Enforcement TCN Lookup:



Privacy Statement

Acknowledge the Privacy Statement

 When applying for or renewing your license, you must agree to the privacy statement regarding electronic fingerprinting within the application.

Important


- If the privacy statement is not received, your fingerprinting results CANNOT be shared with the Department.
- This will delay your application for initial licensure or renewal






Slide 53 Slide 54







Slide 55 Slide 56







Slide 57 Slide 58






Slide 59 Slide 60






Slide 61 Slide 62






Slide 63 Slide 64




OPTOMETRY463.0001 463.001 Purpose; intent. 463.002 Definitions. 463.003 Board of Optometry. 463.004 Board headquarters. 463.005 Authority of the board. 463.0055 Administration and prescription of ocular pharmaceutical agents. 463.0057 Optometric faculty certificate. 463.006 Licensure and certification by examination. 463.007 Renewal of license; continuing education. 463.008 Inactive status. 463.009 Supportive personnel. 463.011 Exhibition of license. 463.012 Prescriptions; filing; release; duplication. 463.013 Optometric services for certain public agencies. 463.0135 Standards of practice. 463.014 Certain acts prohibited. 463.0141 Reports of adverse incidents in the practice of optometry. 463.015 Violations and penalties. 463.016 Grounds for disciplinary action; action by the board. 463.018 Reciprocity. https://www.floridaoptometry.gov and https://www.flhealthsource.gov


Slide 65 Slide 66






Slide 67 Slide 68







Slide 69 Slide 70



Slide 71




Oral Ocular Analgesic Medications May not be administered or prescribed for more than 72 hours without consultation with a physician licensed under chapter 458 or chapter 459 who is skilled in diseases of the eye: Tramadol hydrochloride (Schedule IV) Acetaminophen 300 mg with No. 3 codeine 30 mg * Tylenol #3 (Schedule III)




Slide 73 Slide 74





Slide 75 Slide 76



- Certified optometrists may administer and prescribe ocular pharmaceutical agents as provided in this section for the diagnosis and treatment of ocular conditions of the human eye and its appendages without the use of surgery or other invasive techniques.
- The board shall establish a formulary of topical ocular pharmaceutical agents that may be prescribed and administered by a certified optometrist.
- Changes in the topical formulary rule becomes prescriptible 60 days from the adoption date.
- Any person who requests an addition, deletion, or modification of an authorized topical ocular pharmaceutical agent shall have the burden of proof to show cause why such addition, deletion, or modification should be made.

https://www.floridaoptometry.gov and https://www.flhealthsource.gov, 463.055(4), 64B13-18

Slide 77 Slide 78



Additions of Topical Ocular Pharmaceutical Agents

- Request for changes to the formulary must be filed with the Board
- · Must be in writing
- Brand name, chemical name and concentration
- The FDA approved information sheet
- The date the FDA approved for sale
- Explanation of the usefulness


https://www.floridaoptometry.gov and https://www.flhealthsource.gov, 64B13-18.003


Slide 79






Slide 81 Slide 82






Slide 83 Slide 84





Slide 85 Slide 86






Slide 87 Slide 88




Rule 64B13 Overview a) 64B13-3.002 Responsibility to Patient b) 64B13-3.003 Patient Records (c) 64B13-3.003 Patient Records (c) 64B13-3.005 Entrance Signs (e) 64B13-3.005 Entrance Signs (e) 64B13-3.005 Corporate Lay, and Unlicensed Practice of Optometry (g) 64B13-3.009 False advertising (h) 64B13-3.010 Standards of Practice (l) 64B13-3.012 Prescriptions (l) 64B13-3.015 Performance of Delegated Tasks by non-licensed personnel (k) 64B13-3.019 Address of Record (l) 64B13-3.010 Standards for prescribing controlled substances

Slide 89 Slide 90






Slide 91 Slide 92





Slide 93 Slide 94





Slide 95 Slide 96






Slide 97 Slide 98


Complaint Process 456.073, disciplinary proceeding • Citizen files a complaint through the

- Florida Health Care Form
- DOH reviews complaint and investigation is started if:
 - The complaint is in writing
 - Signed by the complainant
 - Can be anonymous if legally sufficient





Slide 99



Slide 100

PROBABLE CAUSE PANEL

The determination as to whether probable cause exists shall be made by the probable cause panel of


The probable cause panel shall be composed of at least two (2) persons

least one member of the panel must be a current pard member. The other member shall be a s member authorized by the Chair.



https://www.floridaoptometry.gov and https://www.flhealthsource.gov, 64B13-2.008


Slide 101 Slide 102







Slide 103





Slide 105 Slide 106






Slide 107





Slide 109 Slide 110






Slide 111






Slide 113 Slide 114







Slide 115 Slide 116



Who files complaints? Patients Family member of patient Ophthalmologists Optometrists Insurance companies

Slide 117 Slide 118






Slide 119

Exam: An examination was performed OD External roomal bill position, nacidacrimal and option area. OB External roomal bill position, nacidacrimal and option area. OB External roomal bill position, nacidacrimal and option area. OB External roomal bill position, nacidacrimal and option area. OB Cot March vascularization of mathematic critics, nacidation of mathematic critics, nacidation, and collections. OD Cot position and option area. OD Arear Comment. OD Option area. OD Arear Comment. OD Items come of any due affector dramber. OD Items come in will not nebecols. OD Cot parts 0.35 OD Option and option area. OD Option area. OD Cot parts 0.35 OD Option before the area normal disc. Lone User. 78/00D ImpressionOPPlan: ImpressionOPPlan: ImpressionOPPlan: Increased programs of the control option disc. Optional control option disc. Object Date India option. ImpressionOPPlan: Impression




Slide 121 Slide 122







Slide 123

Steroid-Induced Glaucoma General population, 5-6% high steroid responders (IOP elevation >15 mmHg) 29-36% are moderate responders (IOP elevation 6-15 mmHg) Approximately 50% have no significant IOP response 1,2 In one study, 0.1% dexamethasone was associated with an average increase of 22 mm Hg from baseline IOP. 3 Prednisolone acetate, a commonly used postoperative medication, demonstrated an average IOP elevation of 10 mm Hg in patients who were previously identified as steroid responders. 3 Upon cessation of steroids, IOP usually normalizes within one to four weeks. 1 Backer B, Mills DW. JAMA. 1963:185(11):884-886. 2 Kraney JP, Broadway DC. Eye (Lond.) 2006;20(4):407-416 3 Cantril HL et al. Am J Ophthalmol. 1975;79(6):1012-1017.



Slide 125 Slide 126






Slide 127 Slide 128






Slide 129 Slide 130






Slide 131

DO YOU DE ANYONE IN YOUR IMMEDIANT FAMILY INVESTIGATION CIRCLE ANY OF THE POLLOWING SYMPTOMS CLALKOMA MICHAEL DEGINERATION MICHAEL DEGI




Slide 133 Slide 134






Slide 135 Slide 136



If the practitioner is found to have violated the law, the board may impose one or more of the following penalties: *Letter of guidance *Formal notice (citation) on the national practitioner database *Reprimand *Fine *Restriction of practice *Continuing education probation (additional hours in a subject matter) *License suspension *License revocation

Slide 137 Slide 138







Slide 139 Slide 140



463.016 Grounds for disciplinary action; Practicing or offering to practice beyond the scope permitted by law or accepting and performing professional responsibilities which the licensed practitioner knows or has reason to know she or he is not competent to perform.


Slide 141 Slide 142





Slide 143 Slide 144





Slide 145 Slide 146

